Cirdan develops software and imaging solutions for pathology and laboratory diagnostics, including its flagship ULTRA LIS, a next-generation Laboratory Information System that scales from single-site labs to large multi-site laboratories. The company’s products aim to streamline operations, expedite disease diagnosis, and improve patient outcomes and healthcare efficiency. Cirdan’s solutions are deployed in over 200 clinical laboratories and hospitals across 20 countries and six continents. Headquartered in the UK with offices in Canada and Australia, the company was founded in 2010 in Lisburn, Ireland by Dr. Hugh Cormican and Stephen Dunniece. Cirdan plans to use new funding to accelerate delivery capabilities, expand its specialist team, enhance its product offerings, scale operations, and push further global expansion into new markets. Cirdan Imaging provides diagnostic digital health and imaging solutions designed to enhance and speed up patient clinical pathways and pathology laboratory work. Its platform includes specimen imaging solutions, patient and clinician apps, and a laboratory information system that collects critical information in a lean and fast way to reduce diagnostic time and surface new healthcare insights. The platform integrates with digital pathology and AI and is shown to improve efficiency, agility, control, and visibility in labs. Headquartered in the UK with offices in North America and Australia, the company serves clients in over 150 laboratories and hospitals across 20 countries and six continents. Cirdan is experiencing a period of rapid growth and intends to continue expanding with new innovative products and entry into new international markets. The company is led by Stephen Dunniece. Cirdan Imaging develops imaging and informatics technology aimed at accelerating and enhancing medical diagnosis. Its product portfolio includes the ULTRA laboratory information system (ULTRA LIS) and a suite of medical imaging systems. The company was established in 2010 and has additional offices in Canada and Australia. Cirdan employs 32 people and reports a multi‑million pound annual turnover. Growth has been driven in part by a 2013 acquisition of part of GE Healthcare’s business, which provided access to a blue‑chip global customer base. The company plans to use recent funding to strengthen ULTRA LIS, capitalize on a partnership with Kainos, scale operations, enter new markets and increase export sales. Cirdan Imaging develops, manufactures and supplies innovative medical imaging technology used in the diagnosis and management of disease. The company designs and distributes novel medical diagnostic solutions to healthcare customers. It was established in 2010 by CEO Hugh Cormican and CTO Stephen Dunniece and is based in Lisburn, Northern Ireland. Cirdan has been supported by Invest Northern Ireland through Co-Fund NI and QUBIS. Its customer base includes blue-chip companies in the UK, US, Canada, Australia and the Middle East. The company intends to use the recent investment to continue to expand operations.

Total raised

$17M

Funding rounds

4

Latest round

Equity

Latest activity

Oct 2024